Carmat S.A (ALCAR) | Financial Analysis & Statements
Carmat S.A. | Small-cap | Healthcare
Carmat S.A. | Small-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
7.0M
Gross Profit
-23.6M
-336.56%
Operating Income
-40.1M
-572.97%
Net Income
-51.4M
-734.21%
EPS (Diluted)
-€1.15
Balance Sheet Metrics
Total Assets
42.4M
Total Liabilities
93.6M
Shareholders Equity
-51.1M
Cash Flow Metrics
Operating Cash Flow
-43.5M
Free Cash Flow
-44.8M
Revenue & Profitability Trend
Carmat S.A Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 7.0M | 2.8M | 372.0K | 2.3M | 0 |
| Cost of Goods Sold | 30.6M | 33.8M | 28.8M | 42.8M | 24.4M |
| Gross Profit | -23.6M | -31.0M | -28.4M | -40.5M | -24.4M |
| Operating Expenses | 6.6M | 2.4M | 4.8M | 2.9M | 794.0K |
| Operating Income | -40.1M | -41.0M | -44.1M | -48.1M | -28.9M |
| Pre-tax Income | -53.1M | -55.6M | -55.7M | -63.7M | -38.7M |
| Income Tax | -1.7M | -1.7M | -2.1M | -1.9M | -1.7M |
| Net Income | -51.4M | -53.9M | -53.7M | -61.9M | -37.0M |
| EPS (Diluted) | -€1.15 | -€2.09 | -€2.28 | -€3.97 | -€2.85 |
Income Statement Trend
Carmat S.A Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 32.4M | 42.4M | 77.8M | 61.7M | 52.9M |
| Non-Current Assets | 10.1M | 10.7M | 7.5M | 7.4M | 7.0M |
| Total Assets | 42.4M | 53.1M | 85.2M | 69.1M | 59.8M |
| Liabilities | |||||
| Current Liabilities | 19.1M | 20.4M | 12.2M | 13.6M | 12.4M |
| Non-Current Liabilities | 74.5M | 76.4M | 71.0M | 69.1M | 54.1M |
| Total Liabilities | 93.6M | 96.8M | 83.3M | 82.6M | 66.5M |
| Equity | |||||
| Total Shareholders Equity | -51.1M | -43.8M | 2.0M | -13.5M | -6.7M |
Balance Sheet Composition
Carmat S.A Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -49.2M | -52.5M | -51.9M | -60.4M | -37.0M |
| Operating Cash Flow | -43.5M | -59.4M | -52.9M | -78.0M | -53.0M |
| Investing Activities | |||||
| Capital Expenditures | -1.5M | -5.0M | -1.7M | -1.8M | -2.3M |
| Investing Cash Flow | -1.4M | -4.9M | -2.0M | -1.8M | -2.4M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | 41.4M | 15.0M | 68.6M | 65.1M | 25.8M |
| Free Cash Flow | -44.8M | -58.5M | -56.1M | -61.9M | -45.4M |
Cash Flow Trend
Carmat S.A Key Financial Ratios
Valuation Ratios
Forward P/E
-0.18
Price to Sales
3.37
PEG Ratio
-0.18
Profitability Ratios
Profit Margin
-336.56%
Operating Margin
-644.75%
Return on Equity
100.52%
Return on Assets
-64.45%
Financial Health
Current Ratio
1.68
Debt to Equity
-1.13
Beta
1.45
Per Share Data
EPS (TTM)
-€1.15
Book Value per Share
-€0.81
Revenue per Share
€0.16
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| alcar | 24.8M | - | - | 100.52% | -336.56% | -1.13 |
| Eurobio Scientific | 253.4M | 64.74 | 1.42 | 2.26% | 2.58% | 5.46 |
| Affluent Medical | 53.3M | -3.55 | 1.73 | -48.69% | -275.50% | 0.54 |
| Median Technologies | 25.6M | -1.02 | - | 74.31% | -109.93% | -0.98 |
| Novacyt S.A | 34.9M | -0.82 | 0.72 | -57.28% | -212.73% | 24.81 |
| Diagnostic Medical | 24.2M | -8.64 | 1.96 | -20.20% | -5.90% | 141.76 |
Financial data is updated regularly. All figures are in the company's reporting currency.